Alkermes plc stock (IE00B56GVS15): Baird raises price target to $48

Alkermes plc shares hit a 52-week high of $38.94 amid Baird maintaining its rating and lifting the price target to $48.00, signaling confidence in the biotech firm's growth prospects.

Alkermes plc, a biotechnology company focused on neuroscience and oncology therapeutics, saw its shares reach a 52-week high of $38.94 recently, with the stock trading at $38.80 thereafter, according to Investing.com as of May 2026. Concurrently, Baird maintained its rating on the stock while raising the price target to $48.00 from a prior level, as reported by GuruFocus as of May 2026. This development underscores ongoing analyst interest in Alkermes' pipeline amid its US Nasdaq listing, relevant for American retail investors tracking biotech exposure.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Alkermes plc
• Sector/industry: Biotechnology
• Headquarters/country: Ireland
• Core markets: US, neuroscience, oncology
• Home exchange/listing venue: Nasdaq (ALKS)
• Trading currency: USD

Alkermes plc: core business model

Alkermes plc develops innovative medicines using proprietary technologies for central nervous system disorders and oncology. The company leverages its Linker technology and NanoCrystal platforms to create extended-release formulations and solubility-enhanced products. Key approved products include Vivitrol for alcohol and opioid dependence, Aristada for schizophrenia, and Lybalvi for bipolar disorder and schizophrenia, all targeting unmet needs in neuroscience.

Headquartered in Ireland with primary operations in the US, Alkermes focuses on high-barrier-to-entry markets. Its business model emphasizes R&D investment alongside commercial execution, with manufacturing facilities supporting both proprietary and partnered programs. This integrated approach positions it as a mid-cap biotech with US-centric revenue, appealing to investors eyeing American healthcare innovation.

Main revenue and product drivers for Alkermes plc

Revenue primarily stems from neuroscience products, with Vivitrol generating steady sales through its long-acting injectable format for addiction treatment. Aristada and Lybalvi contribute to the schizophrenia portfolio, benefiting from label expansions and payer coverage growth. Oncology programs, including Nemvaleukin in partnership with Takeda, represent upside potential pending clinical readouts.

In recent quarters, product sales have shown resilience amid patent protections and market penetration efforts. The company's focus on specialty pharma differentiates it from pure-play developers, providing cash flow stability for pipeline advancement. US market dynamics, including mental health awareness, drive demand for these therapies.

Industry trends and competitive position

The biotech sector faces volatility from clinical trial outcomes and regulatory shifts, yet neuroscience remains a growth area with rising prevalence of mental health disorders. Alkermes competes with larger players like Eli Lilly and Otsuka in CNS but carves a niche via long-acting injectables, reducing patient non-compliance. Its oncology foray adds diversification as immuno-oncology evolves.

Competitive edges include proprietary delivery tech and a lean cost structure, enabling sustained R&D spend. For US investors, Alkermes offers exposure to domestic healthcare spending trends without the binary risks of early-stage biotechs.

Why Alkermes plc matters for US investors

Listed on Nasdaq under ALKS, Alkermes derives most revenue from the US, aligning with American economic cycles and policy changes like drug pricing reforms. Its products address critical public health issues, from opioid crises to schizophrenia management, supported by Medicare and commercial insurance. Recent share strength reflects broader biotech momentum post-FDA approvals.

Retail investors gain targeted exposure to innovative therapies without single-product concentration risks, bolstered by the firm's Dublin headquarters yet heavy US footprint.

Conclusion

Alkermes plc continues to demonstrate momentum with its recent 52-week high and Baird's upgraded price target to $48.00, highlighting pipeline potential in neuroscience and oncology. While trading above some intrinsic value estimates like GuruFocus' GF Value of $30.58 as of May 2026, the stock's GF Score of 80/100 suggests solid fundamentals. Investors monitor upcoming catalysts amid biotech sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.